GPGrazia Pusole

Grazia Pusole

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Grazia Pusole has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of breakthrough cancer pain in patients with oral mucositis

    by S. Tolu, E. Lai, V. Impera, G. Pusole, A. Pretta, N. Liscia, S. Camera, A. Cubeddu, R. Mascia, A.G. Pireddu, et al.

    Background: Oral mucositis, which typically appears with erythematous and ulcerative lesions of the oral mucosa, is a common affection in cancer patients as a consequence of chemotherapy or radiotherapy or cancer itself. It can compromise nutritional status and quality of life, being a cause of pain, especially during swallowing and inhibiting proper feeding. Furthermore, inflammatory state of oral mucosa can negatively affect absorption of therapy, especially analgesic drugs, causing insufficient efficacy. So alternative administration routes need to be investigated to control algic symptomatology. Intranasal fentanyl formulation is recommended for breakthrough cancer pain (BTCP), it provides fast pain relief and it may be a valid treatment option for these patients, in particular the assumption immediately before meals can allow a better feeding. We investigated efficacy of fentanyl pectin nasal spray in a subset of patients with oral mucositis and its impact on quality of life.

  • Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience

    by E. Lai, S. Tolu, R. Mascia, V. Impera, A. Pretta, N. Liscia, A.G. Pireddu, G. Pusole, S. Camera, A. Cubeddu, et al.

    Background: Breakthrough cancer pain (BTCP) is defined as a temporary exacerbation of algic symptomatology occurring in patients with controlled chronic cancer pain. Tipically BTCP arises with rapid onset, high intensity and has an average duration of 30 minutes. From 64% to 89% of patients with chronic cancer pain have episodes of BTCP and most episodes are unpredictable. Episodes of BTCP are usually treated with short-acting opioid analgesics. Fentanyl, an highly liposoluble opioid molecule, showed efficacy and feasibility in treatment of BTCP in different formulations, including transmucosal and nasal administration. Intranasal fentanyl was reported to be often preferred by patients because of easy spray delivery of the drug and it seemed to be more helpful than transmucosal one in patients with oral mucosal disorders. In our center we studied compliance and satisfaction of patients treated with fentanyl pectin nasal spray for BTCP.

  • Medical management of malignant bowel obstruction: our center experience

    by G. Astara, E. Lai, S. Tolu, R. Mascia, V. Impera, M. Dessì, S. Camera, G. Pusole, A. Cubeddu, A.G. Pireddu, et al.

    Background: Malignant bowel obstruction (MBO) is common in advanced cancer patients. It developes more likely in gastrointestinal or gynaecological tumors with abdominal burden, but it can arise in other cancers too. Its typical symptomps, nausea, vomiting, abdominal pain, impact negatively on patients’ daily life, making MBO a very disabling condition. Surgery is a treatment option only for selected patients who meet surgical criteria. Other patients are usually treated with nasogastric tube to decompress bowel distension, fasting and supportive care. Studies showed that medical treatment with metoclopramide, octreotide and dexamethasone can significatively improve symptoms and quality of life. Octreotide has both antisecretive effects which reduce intestinal fluids improving nausea and vomiting and the power of reducing bowel motility, that can weaken abdominal cramps. Here, we report our center experience of MBO medical treatment.


  • Prognostic neutrophil-to-lymphocyte ratio in head and neck cancer: A single center experience.

    by Pina Ziranu, Elena Massa, Marco Puzzoni, Laura Demurtas, Clelia Madeddu, Grazia Pusole, Alessio Cubeddu, Giorgio Astara, Roberta Mascia, Valeria Pusceddu, et al.

    E17540 Background: The Neutrophil-to-Lymphocytes ratio (NLR) represents a potential prognostic and predictive marker in a different tumor types. The purpose of our study was to investigate the prognostic value of the pretreatment inflammatory marker NLR in patients with head and neck squamous cell carcinoma (HNSCC). Methods: Pretreatment NLR were retrospectively investigated for correlation with overall survival (OS). Kaplan-Meier statistic and long rang test were used. Univariate analysis for categorical and descriptive variables were performed. Results: Thirty-nine patients, from local to advanced stage disease, were included in our analysis. At a median follow up of 9.44 months (2.04 – 30.3), of the total patients 30.7% died and 41.9% had progression of disease. The median PFS was 4.6 months (2.9 – 27.2) and the median OS (mOS) was 18.9 months. Following ROC curve analysis the optimum cut-off value of NLR was 3.93 (p = 0.017). Patient with NLR > 3.92 had a mOS of 11.9 months, whereas the mOS for NLR ≤ 3.92 was 30.3 months (Log-rank p = 0.189). The 1 year Kaplan-Meier estimates of OS for NLR ≤ 3.92 vs. >3.92 was 72% vs. 45% respectively (Log-rank p = 0.243). According to COX univariate analysis, the risk of death increases of 7.7% each unitary rise of NLR mean value (p = 0.3407). Conclusions: In our limited case series NLR was not significantly associated with clinical outcome. Therefore, multicenter studied are needed to determine an optimal NLR cutoff value. [Table: see text]


  • Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications

    by Cinzia Solinas, Grazia Pusole, Laura Demurtas, Marco Puzzoni, Roberta Mascia, Gilberto Morgan, Riccardo Giampieri, Mario Scartozzi


  • Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)

    by M. Puzzoni, G. Pusole, R. Mascia, L. Demurtas, A. Dessì, A. Cubeddu, E. Lai, S. Tolu, P. Ziranu, L. Orgiano, et al.

    Background: Currently we are able to exclude from anti-epidermal growth factor receptor (EGFR) treatment patients with putative refractory colorectal tumours (i.e. those harboring a RAS mutant status). However on the other hand a nonnegligible proportion of patients don't fully benefit from the use of chemotherapy in combination with anti-EGFR treatment (cetuximab or panitumumab), although in the absence of a mutation of the RAS genes. Published research data suggested that EGFR gene copy number, PIK3CA mutations, PTEN mutations or copy number variations and BRAF mutations may all represent predictive determinants for anti-EGFR therapy. However these factors were not incorporated into clinical practice particularly because prospective validation is lacking.

  • REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)

    by L. Demurtas, E. Lai, A. Cubeddu, M. Puzzoni, G. Pusole, S. Tolu, A. Dessì, R. Mascia, V. Pusceddu, G. Astara, et al.

    Background: The introduction of regorafenib represented a significant step forward for metastatic colorectal cancer patients. Available data seem to indicate that a not negligible proportion of patients does not derive any benefit from this treatment and is thus exposed to unnecessary toxicity. Preliminary findings from our group suggested that vascular endothelial growth factor-A (VEGF-A) rs2010963 might have an independent correlation with progression free (PFS) and overall survival (OS). On the other hand further analyses focused on factors such as neutrophil to lymphocyte ratio, platelets count and LDH serum levels to define a biological profile of responding/resistant patients. Unfortunately these factors have been all analyzed separately and, more importantly, retrospectively. A validation is mandatory prior to incorporate findings from these studies into clinical practice.

  • Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-ras and n-ras wild type metastatic colorectal cancer (SUPER- PEAK)

    by G. Pusole, M. Puzzoni, R. Mascia, L. Demurtas, A. Dessì, A. Cubeddu, E. Lai, S. Tolu, P. Ziranu, L. Orgiano, et al.

    Background: Currently we are able to exclude from anti-epidermal growth factor receptor (EGFR) treatment patients with putative refractory colorectal tumours (i.e. those harboring a RAS mutant status). However on the other hand a nonnegligible proportion of patients don't fully benefit from the use of chemotherapy in combination with anti-EGFR treatment (cetuximab or panitumumab), although in the absence of a mutation of the RAS genes. Published research data suggested that EGFR gene copy number, PIK3CA mutations, PTEN mutations or copy number variations and BRAF mutations may all represent predictive determinants for anti-EGFR therapy. However these factors were not incorporated into clinical practice particularly because prospective validation is lacking.

  • REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol)

    by A. Dessì, L. Demurtas, S. Tolu, M. Puzzoni, A. Cubeddu, E. Lai, G. Pusole, R. Mascia, P. Ziranu, L. Orgiano, et al.

    Background: The introduction of regorafenib represented a significant step forward for metastatic colorectal cancer patients. Available data seem to indicate that a not negligible proportion of patients does not derive any benefit from this treatment and is thus exposed to unnecessary toxicity.

  • Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment

    by E. Massa, M. Puzzoni, L. Demurtas, A. Cubeddu, G. Pusole, A. Dessì, R. Fadda, M. Scartozzi

    Background: At the time of diagnosis, 25% of patients (pts) with colorectal cancer (CRC) present synchronous unresectable metastases. The best therapeutic option for this pts is not yet defined: primary tumor resection (PTR) followed by chemotherapy or upfront chemotherapy without PTR?